4-(ethylamino)-5-nitro-2-phenoxy-pyridine | 607373-91-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(ethylamino)-5-nitro-2-phenoxy-pyridine
• 英文别名: N-Ethyl-5-nitro-2-phenoxypyridin-4-amine
• CAS: 607373-91-1
• 化学式: C₁₃H₁₃N₃O₃
• 分子量: 259.265
• InChiKey: TYKQFVLABUHOLQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  80
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(ethylamino)-5-nitro-2-phenoxy-pyridine 在 palladium on activated charcoal 盐酸 、 氢气 、 sodium nitrite 作用下， 以 甲醇 为溶剂， 生成 4-{1-ethyl-6-phenoxy-1H-imidazo[4,5-c]pyridin-2-yl}-1,2,5-oxadiazol-3-amine
  参考文献：
  名称：

  Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

  摘要：

  The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.

  DOI：

  10.1021/jm060873p
• 作为产物：
  描述：

  4-羟基-3-硝基吡啶 在 叔丁基过氧化氢 、 potassium tert-butylate 、 三氯氧磷 作用下， 以 四氢呋喃 、 癸烷 、 氨 、 水 、 甲苯 为溶剂， 反应 25.0h， 生成 4-(ethylamino)-5-nitro-2-phenoxy-pyridine
  参考文献：
  名称：

  Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity

  摘要：

  The discovery, proposed binding mode, and optimization of a novel class of Rho-kinase inhibitors are presented. Appropriate substitution on the 6-position of the azabenzimidazole core provided subnanomolar enzyme potency in vitro while dramatically improving selectivity over a panel of other kinases. Pharmacokinetic data was obtained for the most potent and selective examples and one (6n) has been shown to lower blood pressure in a rat model of hypertension.

  DOI：

  10.1021/jm060873p

文献信息

• [EN] IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DERIVES D'IMIDAZOPYRIDINE EN TANT QU'INHIBITEURS DE KINASE
  申请人：GLAXO GROUP LTD

  公开号：WO2003080610A1

  公开（公告）日：2003-10-02

  A compound of the formula: (I) and-physiologically acceptable salts and or N-oxides thereof wherein, X1 is N or CR.3; X2 is N or CR'4; X3 ,is..N or CR5; X4 is N or CR6 with the proviso that at least one but not more than two of X1, X 2, X,3. and X4 represents N. R1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d formula: (II) wherein X5 is a group selected from N or CR7: and X6, is a group selected from O, S or NR8; X7 and X8; which maybe the same or, different is a group selected from N or CR9; ; X9, is a group selected from O, S or NR8 and X10 is N or CR10 ; X11 , X12 and X13 may be the same or different and selected from a group N or CR11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

  化合物的式子为：（I），其生理上可接受的盐和/或N-氧化物，其中，X1为N或CR.3；X2为N或CR'4；X3为N或CR5；X4为N或CR6，但至少其中一个但不超过两个X1、X2、X3和X4代表N。R1是从a、b、c或d组中选择的5-或6-成员杂环基，式子为：（II），其中X5是从N或CR7选择的基团；X6是从O、S或NR8选择的基团；X7和X8可以相同或不同，是从N或CR9选择的基团；X9是从O、S或NR8选择的基团，X10是N或CR10；X11、X12和X13可以相同或不同，是从N或CR11的基团中选择的；制备它们的过程，包含它们的制药组合物以及它们在医学上的用途。
• Imidazopyridine derivatives as kinase inhibitors
  申请人：Bailey Nicholas

  公开号：US20050197328A1

  公开（公告）日：2005-09-08

  A compound of the formula and physiologically acceptable salts and or N-oxides thereof wherein, X 1 is N or CR 3 ; X 2 is N or CR 4 ; X 3 is N or CR 5 ; X 4 is N or CR 6 . with the proviso that at least one but not more than two of X 1 , X 2 , X 3 and X 4 represents N. R 1 is a 5-, or 6-membered heterocyclic group selected from group a, b, c or d wherein X 5 is a group selected from N or CR 7 and X 6 is a group selected from O, S or NR 8; X 7 and X 8 which may be the same or different is a group selected from N or CR 9; X 9 is a group selected from O, S or NR 8 and X 10 is N or CR 10; X 11 , X 12 and X 13 may be the same or different and selected from a group N or CR 11 ; processes for their preparation, pharmaceutical compositions containing them and their use in medicine.

  式中化合物及其生理上可接受的盐和/或N-氧化物，其中： X1为N或CR3； X2为N或CR4； X3为N或CR5； X4为N或CR6； 但须满足X1、X2、X3和X4中至少一个但不超过两个为N； R1为从a、b、c或d组中选择的5-或6-成员杂环基，其中X5为N或CR7组，X6为O、S或NR8组； X7和X8可以相同或不同，为N或CR9组； X9为O、S或NR8组，X10为N或CR10组； X11、X12和X13可以相同或不同，为N或CR11组； 本发明还涉及其制备方法、包含它们的制药组合物以及它们在医学上的应用。
• IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1490367A1

  公开（公告）日：2004-12-29
• US7348339B2
  申请人：——

  公开号：US7348339B2

  公开（公告）日：2008-03-25